Therefore, investigating PGx interactions of novel genes/variants, other than NUDT15 and TPMT variations, is urgently needed for preventing thiopurine intolerance due to hematological toxicities and improving pediatric ALL care. The gene discussed is TPMT; the disease is acute lymphoblastic leukemia.